Preclinical
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Talk about a welcome Christmas present! Researchers at Flinders University in Australia, working with mice, removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis (‘IPF’) against standard of care
Researchers with the University of California – Los Angeles Health Sciences have identified two major groups of genes that, when mutated, results in overproduction of the tau protein, at least in mice. They published their research in the journal Nature Medicine.
The placenta, sometimes called afterbirth, is described as an organ that develops in the uterus during pregnancy. Although research has been conducted on placentas for decades, three important studies were recently published related to the science of the placenta.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Although most readers will already be aware of it, the biggest story, perhaps the biggest story of the year—certainly the most controversial—involves a Chinese researcher who used CRISPR to modify embryos to be resistant to HIV, and the recent birth of a set of twins.
Scientists from a consortium of prominent research institutions studied the entire genomes of more than 20,000 people with attention deficit/hyperactivity disorder (ADHD) and compared them to the genomes of 35,000 who did not have ADHD. They identified 12 genetic variants in the ADHD group, suggesting an increased risk of ADHD compared to those without the variants.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
Shares of Boston-based Zafgen, Inc. plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.
Sareum Holdings plc has today reported new preclinical data that support its ongoing clinical trial with SRA737 as a monotherapy in ovarian cancer.
PRESS RELEASES